Adding the investigational IDO-pathway inhibitor indoximod to checkpoint inhibitor therapy resulted in a 52% overall response rate in patients with advanced melanoma enrolled in a phase II trial. The combination strategy has potential as an alternative for patients whose tumors do not respond to standard therapy.
http://ift.tt/2ri2P4k
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου